atezolizumab
Roche
the goblet study abstract at #wcgic2022 shows the first three pancreatic cancer patients all had partial responses to pelareorep combination therapy, this cohort has already met the expansion criteria to allow for additional patient enrollment, read more: 
Oncolytics is developing pelareorep, an IV delivered I-O virus, promoting an inflamed tumor: waking the immune system.
Contact company directly: https://t.co/LZFYrBMV17